Sign In
Buy ATNM
$1.11
-0.0500 (-4.31%)
At Close: Jun 04, 2026
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
10:15am, Thursday, 08'th Aug 2024
LOS ANGELES , Aug. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Actinium Pharmaceuti
Did Actinium Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– ATNM
11:45pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible v
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Actinium Pharmaceuticals, Inc. ("Actinium") (NYSE:ATNM) concerning possible v
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Actinium Pharmaceuticals, Inc. - ATNM
12:00pm, Wednesday, 07'th Aug 2024
NEW YORK, NY / ACCESSWIRE / August 7, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE:ATNM). Such investors ar
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
02:39pm, Monday, 05'th Aug 2024
U.S. stocks traded lower toward the end of trading, with the S&P 500 dipping more than 100 points on Monday.
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
11:21am, Monday, 05'th Aug 2024
On Monday, the FDA determined that Actinium Pharmaceuticals, Inc.'s ATNM Phase 3 SIERRA trial is not adequate to support a Biologics License Application (BLA) filing for Iomab-B despite its statisti
Actinium Pharma's stock craters after FDA says Phase 3 trial of leukemia treatment not enough for BLA
08:22am, Monday, 05'th Aug 2024
The stock of biotech Actinium Pharmaceutics Inc. tumbled 65% early Monday, after the Food and Drug Administration said a late-stage trial of its Iomab-B leukemia treatment is not enough to support a r
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
07:00am, Monday, 05'th Aug 2024
FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpoint Additional head-to-head randomized clinical tria
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs - Pertains
- Sickle cell disease affects approximately 100,000 patients in the U.S. annually and is a debilitating and life-threatening condition with high unmet need - Current conditioning with non-targeted c
Actinium Pharmaceuticals to Present at the 3rd Annual Targeted Radiopharmaceuticals Summit US
07:30am, Thursday, 25'th Jul 2024
Presentation to highlight positive outcomes of Iomab-B led bone marrow transplant in difficult to treat TP53 patients and the mutation-agnostic mechanism of Actimab-A for patients with relapsed or ref
NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production
07:00am, Monday, 22'nd Jul 2024
BELOIT, Wis. & OTTAWA, Ontario--(BUSINESS WIRE)--NorthStar Medical Radioisotopes and BWXT Medical Sign Supply Agreement Supporting Actinium-225 Production.
3 Under-$10 Biotech Stocks That Could Make You Rich
02:23pm, Thursday, 11'th Jul 2024
Low-cap biotech companies are a high-risk but high-reward investment choice. If their clinical trials are successful, that can often mean an explosion in value as investors anticipate a buyout.
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
05:05pm, Tuesday, 02'nd Jul 2024
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.
Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
10:45am, Thursday, 20'th Jun 2024
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year.
